Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | CES1 | P23141 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273163 | 0.82 | CA12 (0.47) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL10740779 | 0.81 | SLC6A2 (0.54) | SLC6A2CHRNB4CHRNA3SLC6A3CHRNB2 | |
| SCHEMBL6081855 | 0.79 | PGR (0.46) | CES2CES1RAB9AALDH1A1NPC1 | |
| SCHEMBL8015553 | 0.79 | CES2 (0.61) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL4273531 | 0.78 | CES2 (0.56) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL2599161 | 0.78 | CES2 (0.64) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL5883596 | 0.78 | CES2 (0.59) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL15007480 | 0.78 | CES2 (0.64) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL31351227 | 0.77 | CES2 (0.54) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL312334 | 0.76 | CES2 (0.57) | CES2CES1SLC6A2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | claimed |
| US-7608740-B2 | Method of synthesizing key intermediates for the production of camptothecin derivatives | Avra Laboratories Pvt. Ltd (IN) | 2009-10-27 | — | — | US | claimed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | claimed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | claimed |
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-7608740-B2 | Method of synthesizing key intermediates for the production of camptothecin derivatives | Avra Laboratories Pvt. Ltd (IN) | 2009-10-27 | — | — | US | disclosed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | DHPS, TOP2A, HCCS | CES2 1018/4885CES1 1571/4885SLC6A2 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.